ストックスクリーナーアプリを入手
2.94
3.52%
0.10
アフターアワーズ：
2.91
-0.03
-1.02%
前日終値:
$2.84
開ける：
$2.82
24時間の取引高:
1.60M
Relative Volume:
1.21
時価総額：
$782.40M
収益：
-
当期純損益:
$-208.38M
株価収益率:
-2.4706
EPS:
-1.19
ネットキャッシュフロー:
$-156.57M
1週間 パフォーマンス:
-4.55%
1か月 パフォーマンス:
-33.78%
6か月 パフォーマンス:
-23.44%
1年 パフォーマンス:
-34.38%
1日の値動き範囲:
$2.76
$3.0498
1週間の範囲:
$2.69
$3.25
52週間の値動き範囲:
$2.69
$7.45
Autolus Therapeutics Plc Adr Stock (AUTL) Company Profile
AUTL を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| AUTL | 2.94 | 782.40M | 0 | -208.38M | -156.57M | -1.19 |
| VRTX | 450.97 | 116.14B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 738.00 | 81.10B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 605.92 | 36.23B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 244.89 | 31.59B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 113.13 | 27.12B | 3.30B | -501.07M | 1.03B | 11.54 |
Autolus Therapeutics Plc Adr Stock (AUTL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-11-09 | 開始されました | Deutsche Bank | Buy |
| 2023-03-27 | 再開されました | Wells Fargo | Overweight |
| 2023-03-17 | 開始されました | Bryan Garnier | Buy |
| 2021-06-14 | アップグレード | Jefferies | Hold → Buy |
| 2021-01-29 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-12-28 | 再開されました | H.C. Wainwright | Buy |
| 2020-07-31 | 開始されました | JP Morgan | Overweight |
| 2020-07-22 | 開始されました | SunTrust | Buy |
| 2020-04-22 | 開始されました | Mizuho | Buy |
| 2019-09-23 | 開始されました | Needham | Buy |
| 2019-05-17 | 繰り返されました | H.C. Wainwright | Buy |
| 2018-10-24 | 開始されました | H.C. Wainwright | Buy |
すべてを表示
Autolus Therapeutics Plc Adr (AUTL) 最新ニュース
These Numbers Prove Just How Vibrant The Ocugen Inc (NASDAQ: OCGN) Stock Has Been - Stocks Register
Autolus stock upgraded as obe-cel approval drives optimism for commercial potential - Investing.com
Autolus Therapeutics to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024 - Barchart
Does MP Materials Corporation (NYSE: MP) Still Need To Convince Analysts? - Stocks Register
Hafnia Ltd (NYSE: HAFN) Drops -3.00%, Turning Investors Away - Stocks Register
Autolus Therapeutics (AUTL): High-Growth UK Stock in Cancer Therapy - Yahoo Finance
Why Autolus Therapeutics plc (AUTL) is the Penny Stock with the Biggest Upside Potential According to Analysts - Yahoo Finance
PDD Holdings Inc ADR (NASDAQ: PDD) Has Been Trading Down. What Are The Prospects For The Future? - Stocks Register
What Do Wall Street Analysts Think About Moderna Inc (NASDAQ: MRNA) Stock? - Stocks Register
Before You Invest, Make Sure You Check This Autolus Therapeutics plc ADR (NASDAQ: AUTL) Analysis - Stocks Register
Autolus Therapeutics plc ADR (AUTL)’s stock rises to 4.14 per share - US Post News
Autolus Therapeutics plc ADR: -44.83% Growth from 52-Week Low, Yet Analysts Divided - The InvestChronicle
A better buy-in window may exist right now for Autolus Therapeutics plc ADR (AUTL) - SETE News
Upward Trajectory: Autolus Therapeutics plc ADR (AUTL) Posts a Slidee, Closing at 3.98 - The Dwinnex
Autolus Therapeutics plc ADR (AUTL) is an excellent investment, but the stock is overvalued/undervalued right now - US Post News
Are Smart Investors Making the Right Decision? Autolus Therapeutics plc ADR (AUTL) - SETE News
Autolus Therapeutics plc ADR (AUTL) Stock: The Story of a 52-Week Stock Range - The InvestChronicle
Autolus Therapeutics plc ADR (AUTL)’s stock chart: A technical perspective - US Post News
Stock Performance Spotlight: Autolus Therapeutics plc ADR (AUTL) Ends the Day at 3.63, Up by 4.31 - The Dwinnex
A look into Autolus Therapeutics plc ADR (AUTL)’s deeper side - SETE News
Are Autolus Therapeutics plc ADR (AUTL) shares a good deal now? - US Post News
Autolus Therapeutics plc ADR (AUTL)’s Market Momentum: Closing Strong at 3.73, Down -3.12 - The Dwinnex
Autolus Therapeutics (NASDAQ:AUTL) Shares Down 4.8% - MarketBeat
Autolus Therapeutics names new Chief Development Officer - Investing.com India
Autolus Therapeutics names new Chief Development Officer By Investing.com - Investing.com South Africa
Autolus Therapeutics plc (NASDAQ:AUTL) Short Interest Down 8.0% in August - Defense World
Autolus Therapeutics plc ADR (AUTL) looking to reclaim success with recent performance - SETE News
Autolus Therapeutics plc ADR (AUTL) Stock: Navigating a Year of Volatility - The InvestChronicle
Autolus Therapeutics plc (NASDAQ:AUTL) Shares Acquired by Daiwa Securities Group Inc. - Defense World
Autolus Therapeutics plc ADR (AUTL)’s stock price in review: A technical analysis - US Post News
Autolus Therapeutics (NASDAQ:AUTL) Shares Gap Up to $4.08 - MarketBeat
Financial Metrics Check: Autolus Therapeutics plc ADR (AUTL)’s Ratios for Trailing Twelve Months - The Dwinnex
Autolus secures £18.5M for facility upgrades - Investing.com
Autolus Therapeutics plc ADR (AUTL) is looking forward to a strong quarter - SETE News
Trading Day Review: Autolus Therapeutics plc ADR (AUTL) Gains Momentum, Closing at 4.12 - The Dwinnex
Autolus Therapeutics plc ADR (AUTL) presents a great opportunity, but the stock is slightly overvalued - US Post News
Autolus Therapeutics (NASDAQ:AUTL) Stock Price Up 6% - MarketBeat
Autolus Therapeutics (NASDAQ:AUTL) Stock Price Down 3.4% - MarketBeat
It is Poised to be a Bull Market for Autolus Therapeutics plc ADR (AUTL) - SETE News
Contrasting Autolus Therapeutics (NASDAQ:AUTL) & ZIVO Bioscience (NASDAQ:ZIVO) - Defense World
Lucinda Crabtree joins Oxford Biomedica as Chief Financial Officer today - GlobeNewswire Inc.
Autolus reports promising results for obe-cel in leukemia study - Investing.com India
Views of Wall Street’s Leading Experts on Autolus Therapeutics plc ADR - SETE News
Is Autolus Therapeutics plc ADR (AUTL) a good investment opportunity? - US Post News
SG Americas Securities LLC Purchases 169,387 Shares of Autolus Therapeutics plc (NASDAQ:AUTL) - Defense World
Take off with Autolus Therapeutics plc ADR (AUTL): Get ready for trading - SETE News
Examining Autolus Therapeutics plc ADR (AUTL) stock is warranted - US Post News
Autolus Therapeutics plc ADR (AUTL)’s Market Momentum: Closing Strong at 3.75, Up 1.90 - The Dwinnex
Autolus Therapeutics (NASDAQ:AUTL) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
Financial Survey: Autolus Therapeutics (NASDAQ:AUTL) and Cognition Therapeutics (NASDAQ:CGTX) - Defense World
Autolus Therapeutics (NASDAQ:AUTL) Shares Gap Up to $3.64 - Defense World
Autolus Therapeutics Plc Adr (AUTL) 財務データ
収益
当期純利益
現金流量
EPS
1.89%
2.08%
大文字化:
|
ボリューム (24 時間):